ArticlePloS one2009
Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit.British journal of clinical pharmacology · 2013Pooled it
- RhEPO improves time to exhaustion by non-hematopoietic factors in humans.European journal of applied physiology · 2016Trial
- Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder.Trials · 2010Trial
- A direct effect of the hematocrit on blood glucose: Evidence from hypoxia- and erythropoietin-treated mice.Science advances · 2025Article
- Review
- Article
- Comparative Analysis of MicroRNA Expression Profiles Between Skeletal Muscle- and Adipose-Derived Exosomes in Pig.Frontiers in genetics · 2021Article
- Erythropoietin Non-hematopoietic Tissue Response and Regulation of Metabolism During Diet Induced Obesity.Frontiers in pharmacology · 2021Review
- No effect of 10 weeks erythropoietin treatment on lipid oxidation in healthy men.Endocrine connections · 2020Article
- Erythropoietin regulates metabolic response in mice via receptor expression in adipose tissue, brain, and bone.Experimental hematology · 2020Review
- Effects of Erythropoietin in White Adipose Tissue and Bone Microenvironment.Frontiers in cell and developmental biology · 2020Review
- Erythropoietin suppresses hepatic steatosis and obesity by inhibiting endoplasmic reticulum stress and upregulating fibroblast growth factor 21.International journal of molecular medicine · 2019Article
- The Many Facets of Erythropoietin Physiologic and Metabolic Response.Frontiers in physiology · 2019Review
- Article
- Article
- Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines.International journal of molecular sciences · 2016Review
- Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo.Lipids in health and disease · 2016Article
- Non-hematopoietic effects of endogenous erythropoietin on lean mass and body weight regulation.Obesity (Silver Spring, Md.) · 2016Article
- Erythropoietin regulates POMC expression via STAT3 and potentiates leptin response.Journal of molecular endocrinology · 2016Article
- Erythropoietin Does Not Enhance Skeletal Muscle Protein Synthesis Following Exercise in Young and Older Adults.Frontiers in physiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythropoietin can be over-expressed in skeletal muscles by gene electrotransfer, resulting in 100-fold increase in serum EPO and significant increases in haemoglobin levels. Earlier studies have suggested that EPO improves several metabolic parameters when administered to chronically ill kidney patients. Thus we applied the EPO over-expression model to investigate the metabolic effect of EPO in vivo.At 12 weeks, EPO expression resulted in a 23% weight reduction (P<0.01) in EPO transfected obese mice; thus the mice weighed 21.9+/-0.8 g (control, normal diet,) 21.9+/-1.4 g (EPO, normal diet), 35.3+/-3.3 g (control, high-fat diet) and 28.8+/-2.6 g (EPO, high-fat diet). Correspondingly, DXA scanning revealed that this was due to a 28% reduction in adipose tissue mass.The decrease in adipose tissue mass was accompanied by a complete normalisation of fasting insulin levels and glucose tolerance in the high-fat fed mice. EPO expression also induced a 14% increase in muscle volume and a 25% increase in vascularisation of the EPO transfected muscle. Muscle force and stamina were not affected by EPO expression. PCR array analysis revealed that genes involved in lipid metabolism, thermogenesis and inflammation were increased in muscles in response to EPO expression, while genes involved in glucose metabolism were down-regulated. In addition, muscular fat oxidation was increased 1.8-fold in both the EPO transfected and contralateral muscles.In conclusion, we have shown that EPO when expressed in supra-physiological levels has substantial metabolic effects including protection against diet-induced obesity and normalisation of glucose sensitivity associated with a shift to increased fat metabolism in the muscles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.